Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q3 2025 · 10-Q
Revenue$13.29M$13.29M+40.2% vs Q3 2024 Net Income-$48.22M-$48.22MN/M vs Q3 2024 EPS Diluted-$0.21-$0.21N/M vs Q3 2024 Operating Income-$49,114,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$36,167,000N/M Margins · derivedOperating margin-369.4%−11.6 pt vs Q3 2024
Net margin-362.7%−37.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 5, 2025 · 36 d after period end